XBIO - Xenetic Biosciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
-0.0200 (-1.03%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.9500
Bid1.8500 x 3100
Ask2.7500 x 900
Day's Range1.9300 - 2.0400
52 Week Range1.3690 - 8.9500
Avg. Volume65,481
Market Cap21.139M
Beta (3Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.1370
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • ACCESSWIRE19 days ago

    Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering

    FRAMINGHAM, MA / ACCESSWIRE / March 5, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on the acquisition, research and development of novel oncology therapeutics, including next-generation cellular immunotherapies for difficult to treat cancers, including B-cell Lymphomas, as well as improved biologic drugs, today announced it has entered into a securities purchase agreement with a single accredited institutional investor to purchase approximately $3.1 million of the Company’s common stock (the "Common Stock") (or pre-funded warrants to purchase Common Stock in lieu thereof) in a registered direct offering (the "Offering") and warrants to purchase shares of Common Stock in a concurrent private placement. The combined purchase price for one share of Common Stock (or pre-funded warrants to purchase Common Stock in lieu thereof) and each warrant will be $2.00.

  • ACCESSWIRE20 days ago

    Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform

    LEXINGTON, MA / ACCESSWIRE / March 4, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its agreement to acquire the novel CAR T ("Chimeric Antigen Receptor T Cell") platform technology, called "XCART," a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas. The XCART technology, developed by The Scripps Research Institute ("Scripps") in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.

  • What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength
    Simply Wall St.4 months ago

    What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength

    Xenetic Biosciences Inc (NASDAQ:XBIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is XBIO Read More...

  • Why Xenetic Biosciences Just Surged 28 Percent
    InvestorPlace7 months ago

    Why Xenetic Biosciences Just Surged 28 Percent

    Nanocap stocks are inherently risky in the stock market, but can certainly pay off for speculators when they go up. Xenetic Biosciences Inc. (NASDAQ:XBIO) surged 28%, up twofold from the $2 level the stock has been stuck at over the last year. At a closing price of $4.08 on Monday, Aug. 13, XBIO stock is still well below the $8.95 intraday high set in late-June.

  • ACCESSWIRE7 months ago

    Xenetic Biosciences Oncology Phase II Trial in Process, Pipeline Overview

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Xenetic Biosciences, Inc. (XBIO), a clinical-stage biopharmaceutical company. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. In 2018, an estimated 63,000 cases of endometrial cancer will be diagnosed in the U.S., and an estimated 11,000 disease-associated deaths will occur.

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday’s trading session. Shares of Antares Pharma also climbed higher despite any news. It was momentum that kept the stock going after the company announced last week that it would be working with Pfizer.

  • ACCESSWIRE9 months ago

    Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock

    Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.

  • Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Here’s How It Performed Recently
    Simply Wall St.10 months ago

    Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Here’s How It Performed Recently

    Understanding Xenetic Biosciences Inc’s (NASDAQ:XBIO) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...